Travere Therapeutics, Inc. TVTX Debt-to-equity

Debt-to-equity at other companies

Vertex PharmaceuticalsVRTX

0.1×0.0×

Jade BiosciencesJBIO

0×—

Vera TherapeuticsVERA

0.2×0.0×

Eton Pharmaceuticals, Inc.ETON

1×-0.2×

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

ANI PharmaceuticalsANIP

0.5×-0.2×

FAQ

What is Travere Therapeutics, Inc.'s debt-to-equity?

Travere Therapeutics, Inc. (TVTX) reported debt-to-equity of 0.2× in Q1 2026.

How has Travere Therapeutics, Inc.'s debt-to-equity changed year-over-year?

Travere Therapeutics, Inc.'s debt-to-equity decreased by 94.2% year-over-year, from 2.7× to 0.2×.

What is the long-term trend for Travere Therapeutics, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s debt-to-equity has grown at a -1.9% compound annual growth rate (CAGR), from 0.2× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.